CB Therapeutics

cbthera.com →

-75%

est. 2Y upside i

HealthcareSeries A

Fermentation-derived natural products to solve health problems

Rank

#2618

Sector

Biotechnology

Est. Liquidity

~3Y

Data Quality

Data: Medium

CB Therapeutics operates in the high-growth precision fermentation and synthetic biology sectors, with an estimated $3.5M in revenue and $9.1M in total funding.

Last updated: March 10, 2026

Bull (17%)+300%

CB Therapeutics achieves significant breakthroughs in clinical development for its therapeutic compounds, leading to successful Phase 1/2 trials and attracting a major pharmaceutical acquisition or a substantial Series B/C round at a valuation of $320M+ (4x current estimated valuation).

Base (38%)+50%

The company continues to make steady progress in R&D and expands its commercial supply of biosynthetic compounds for research and nutraceutical markets, growing revenue to ~$7M-$10M. This justifies a modest valuation increase to $120M, reflecting continued execution but no major breakout.

Bear (45%)-80%

High capital intensity, regulatory hurdles, or intense competition from well-funded incumbents lead to slower-than-expected progress and a challenging fundraising environment. This results in a down round or significant financial distress, wiping out most common stock value, with the company valued at $16M or less.

Est. time to liquidity~3.0 years

Preference Stack Risk

moderate

Investors hold $9.1M in liquidation preferences ahead of common stock, representing 11.375% of the assumed $80M valuation.

Dilution Risk

high

As a Series A company with high capital intensity and $9.1M total funding, significant future funding rounds are expected, leading to substantial dilution for current equity holders.

Secondary Liquidity

none

There is no indication of active secondary markets or tender offers for CB Therapeutics' equity at this early stage.

Questions to Ask at the Interview

Strategic questions based on CB Therapeutics's data — designed to show you've done your homework.

  • 1

    “Given the 'very high' capital intensity and the need for significant R&D, what is CB Therapeutics' detailed long-term funding strategy beyond its Series A, and what specific milestones are critical for securing the next substantial funding round?”

  • 2

    “How does CB Therapeutics plan to maintain and strengthen its 'moderate' competitive moat against dominant incumbents and well-funded competitors like MindMed and COMPASS Pathways, especially as they expand their own synthetic biology capabilities?”

  • 3

    “Considering the estimated $3.5M in revenue and the joint venture with atai Life Sciences, how is the company prioritizing its diverse revenue streams (therapeutics, food ingredients, research supply) to maximize growth and achieve profitability within the next 2-3 years?”

Community

Valuation Sentiment

Our model estimates -75% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.